EPS for Orgenesis Inc. (ORGS) Expected At $-0.01 as of July, 16

June 27, 2018 - By Daniel Cummings

Orgenesis Inc. (OTCMKTS:ORGS) Corporate Logo

Orgenesis Inc. (OTCMKTS:ORGS)’s earnings release is expected by WallStreet on July, 16, as reported by RTT. Last quarter $-0.52 EPS was reported. Analysts predicts -98.08 % EPS growth this quarter. ORGS is hitting $8.81 during the last trading session, after decreased 0.23%.Currently Orgenesis Inc. is downtrending after 7.14% change in last June 27, 2017. ORGS has also 12,537 shares volume. ORGS underperformed by 19.71% the S&P500.

Orgenesis Inc., a service and research company, focus on the development and manufacture of cell therapy for advanced medicinal products in the field of regenerative medicine industry.The firm is valued at $96.00 million. It operates through two divisions, Contract Development and Manufacturing Organizations and Cellular Therapy (CT) Business.Currently it has negative earnings. The CDMO segment specializes in cell therapy development for advanced medicinal products.

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.